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The TRAF-Interacting Protein (TRIP) Is a Regulator
of Keratinocyte Proliferation
Ste´phanie Almeida1, Stephan Ryser1, Magdalena Obarzanek-Fojt1, Daniel Hohl1 and Marcel Huber1
The TRAF-interacting protein (TRIP/TRAIP) is a RING-type E3 ubiquitin ligase inhibiting tumor necrosis factor-a
(TNF-a)-mediated NF-kB activation. TRIP ablation results in early embryonic lethality in mice. To investigate TRIP
function in epidermis, we examined its expression and the effect of TRIP knockdown (KD) in keratinocytes. TRIP
mRNA expression was strongly downregulated in primary human keratinocytes undergoing differentiation
triggered by high cell density or high calcium. Short-term phorbol-12-myristate-13-acetate (TPA) treatment or
inhibition of phosphatidylinositol-3 kinase signaling in proliferative keratinocytes suppressed TRIP transcrip-
tion. Inhibition by TPA was protein kinase C dependent. Keratinocytes undergoing KD of TRIP expression by
lentiviral short-hairpin RNA (shRNA; T4 and T5) had strongly reduced proliferation rates compared with control
shRNA. Cell cycle analysis demonstrated that TRIP-KD caused growth arrest in the G1/S phase. Keratinocytes
with TRIP-KD resembled differentiated cells consistent with the augmented expression of differentiation
markers keratin 1 and filaggrin. Luciferase-based reporter assays showed no increase in NF-kB activity in TRIP-
KD keratinocytes, indicating that NF-kB activity in keratinocytes is not regulated by TRIP. TRIP expression was
increased by B2-fold in basal cell carcinomas compared with normal skin. These results underline the
important role of TRIP in the regulation of cell cycle progression and the tight linkage of its expression to
keratinocyte proliferation.
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INTRODUCTION
Protein ubiquitination is a post-translational modification that
controls cellular fates of proteins. Covalent ubiquitin attach-
ment to lysine residues of substrates is catalyzed by the
ubiquitin-activating enzyme E1, the ubiquitin-conjugating
enzyme E2, and the ubiquitin-protein ligase E3 (Evans, 2005).
The tumor necrosis factor (TNF) receptor-associated factor
(TRAF)-interacting protein (TRIP/TRAIP) is a member of the
RING-type E3 ubiquitin ligase family that undergoes auto-
ubiquitination but its in vivo substrate(s) have not yet been
identified (Besse et al., 2007). TRIP is composed of the NH2-
terminal RING finger motif that is followed by coiled-coil and
leucine zipper-like domains. TRIP interacts with TRAFs and
represses NF-kB signaling (Lee and Choi, 1997; Besse et al.,
2007). This inhibition is independent of the E3 ubiquitin
ligase activity and occurs probably by interference with
receptor recruitment of TRAF proteins (Lee and Choi, 1997;
Wong et al., 1998; Regamey et al., 2003). CYLD and Syk,
the two regulators of NF-kB signaling (Yamada et al.,
2001; Brummelkamp et al., 2003; Kovalenko et al., 2003;
Trompouki et al., 2003; Chung et al., 2007; Lim et al., 2007;
Zhou and Geahlen, 2009), also interact with TRIP (Regamey
et al., 2003; Zhou and Geahlen, 2009). Both are tumor
suppressors either in keratinocytes (Bignell et al.,
2000; Lee et al., 2005) or melanocytes and breast cancer
cell lines (Coopman et al., 2000; Moroni et al., 2004; Bailet
et al., 2009), suggesting that TRIP could be involved in
tumorigenesis.
TRIP is expressed in normal tissues and in nonmalignant
and highly invasive breast cancer cell lines (Lee and Choi,
1997; Regamey et al., 2003; Zhou and Geahlen, 2009).
Homozygous TRIP knockout mice died early in embryonic
development (E7) because of proliferation defects and
massive apoptosis (Park et al., 2007). Moreover, TRIP
enhances TNF-induced apoptosis in 293 cells, human breast
cancer cell lines, and in male rodent brain (Lee and Choi,
1997; Krishnan et al., 2009; Zhou and Geahlen, 2009).
Conversely, knockdown (KD) of TRIP by small interfering
RNAs in NIH3T3 cells leads to higher susceptibility to
apoptosis induced by treatment with TNF-a and cyclohexi-
mide (Park et al., 2007), whereas induced apoptosis is not
affected by TRIP in breast cancer cell lines (Zhou and
Geahlen, 2009) or L929 murine fibroblasts (Besse et al.,
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2007). TRIP mRNA is strongly reduced when lymphocytes
are stimulated by anti-T-cell receptor and anti-CD28 anti-
bodies (Lee and Choi, 1997). These data suggested that TRIP
may have a role in the regulation of proliferation and survival
in a cell line-specific manner.
Epidermal homeostasis requires a fine-tuned balance
between proliferation and differentiation of keratinocytes.
The inability of keratinocytes to respond to stimuli for cell
cycle exit and differentiation leads to the formation of tumors.
Therefore, the aim of this study was to investigate the role of
TRIP in the regulation of proliferation and differentiation of
primary human keratinocytes. The results showed that TRIP is
mainly expressed in proliferative primary keratinocytes but is
strongly downregulated during differentiation or by addition
of phosphatidylinositol-3 kinase (PI3K) or mammalian target
of rapamycin (mTOR) inhibitors. TRIP knockdown with short-
hairpin RNA (shRNA) introduced by lentiviral infection
decreased keratinocyte proliferation and caused cell cycle
arrest in the G1/S phase. Furthermore, TRIP expression was
increased in basal cell carcinomas (BCCs). The results
demonstrated that TRIP transcription is linked to keratinocyte
proliferation and suggest that TRIP is required for cell
proliferation and/or survival, and may be directly or indirectly
connected to BCC formation.
RESULTS
TRIP is downregulated during epidermal differentiation
To understand the role of TRIP in keratinocytes, TRIP mRNA
expression was examined during epidermal proliferation and
differentiation. Normal human foreskin keratinocytes
(NHEKs) were cultured in low-calcium EpiLife medium
(Cascade Biologics, Basel, Switzerland) to 80–90% con-
fluency (day 0). To study the effect of high cell density (Lee
et al., 1998) or high calcium (Hennings et al., 1980), two
inducers of keratinocyte differentiation, on TRIP mRNA
expression, NHEKs were cultured for 4 additional days (day 4)
in either low-calcium medium or medium supplemented
with 1.2mM calcium. Quantitative reverse transcriptase PCR
(qRT-PCR) analysis showed that TRIP mRNA was strongly
downregulated by high cell density (Figure 1a) or by high
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Figure 1. TRAF-interacting protein (TRIP) mRNA expression is repressed by keratinocyte differentiation or cell growth arrest. (a) Change in expression
levels of TRIP and keratin 1 (HK1) mRNAs in response to increasing cell density or (b) to increasing calcium concentration in normal human foreskin
keratinocytes (NHEKs). (c) Time course of TRIP mRNA level in NHEKs after phorbol-12-myristate-13-acetate (TPA; 100 nM, 2 hours) treatment (white columns)
compared with vehicle-treated cells (black columns). (d) TRIP mRNA level in NHEKs at 24 hours after treatment with TPA (white columns) compared with
vehicle-treated cells (black columns) in the presence or absence of 10 mM GF109203X. The results are shown as mean±SD from three (a, b, d) or six
(c) independent experiments. **Po0.01, ***Po0.001 versus day 0 (a, b) or vehicle-treated cells (c, d).
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calcium (Figure 1b), whereas expression of the differentiation
marker keratin 1 was increased.
Protein kinase C (PKC) is a key mediator of Ca2þ - and cell
confluency-dependent keratinocyte differentiation (Lee et al.,
1998; Tibudan et al., 2002; Sakaguchi et al., 2003; Jerome-
Morais et al., 2009). To examine whether PKC signaling is
involved in TRIP downregulation during keratinocyte differ-
entiation, we used the activator phorbol-12-myristate-13-
acetate (TPA) or the inhibitor GF109203X to manipulate PKC
activity. Analysis by qRT-PCR showed that TRIP mRNA level
was repressed in keratinocytes cultured in low-calcium
medium 24hours after TPA treatment (100 nM, 2 hours)
compared with vehicle control (Figure 1c). Addition of
10 mM GF109203X for 24 hours, starting 60min before TPA
treatment, reversed TPA-induced downregulation of TRIP
(Figure 1d), indicating that TRIP mRNA expression is
regulated by PKC activation. Therefore, TRIP expression is
strongly suppressed during keratinocyte differentiation, sug-
gesting that TRIP may have an important role in proliferative
keratinocytes.
To determine whether TRIP mRNA synthesis was regulated
by other signaling pathways, NHEKs cultured in low-calcium
medium were exposed for 24 hours to inhibitors of MEK1
(PD98059), c-Jun N-terminal kinase (SP600125), PI3K
(LY294002), p38 (SB203580, SB202190), and EGFR
(AG1478). Only the inhibition of PI3K significantly sup-
pressed TRIP transcription (Figure 2a). A downstream target of
PI3K signaling is mTOR (Thomas and Hall, 1997; Hirsch
et al., 2008). Treating NHEKs in low-calcium medium with
the mTOR inhibitor rapamycin (5 and 20 mM) for 24 hours
significantly reduced TRIP expression (Figure 2b), identifying
the TRIP gene as a target of PI3K–mTOR signaling in
keratinocytes.
Knockdown of TRIP in human keratinocytes suppressed cell
proliferation
To investigate further the function of TRIP in proliferating
keratinocytes, pLKO.1-puro-based puromycin-selectable
shRNA lentiviral vectors T1–T5 were used to stably repress
TRIP expression. As the endogenous TRIP protein is not easily
detectable by western blot, TRIP KD efficiency of T1–T5 was
first assessed by co-transfecting T1–T5 or control vectors
together with pEKTRIP and pHA-lacZ plasmids into 293T
cells. The pEKTRIP plasmid expressed a green fluorescent
protein (GFP)–TRIP mRNA that was translated into GFP
protein because of a stop codon between the GFP and TRIP
complementary DNAs (cDNAs); allowing to use the GFP
level to monitor TRIP mRNA quantity. The pHA-LacZ
plasmid expressing HA-b-galactosidase was used to normal-
ize transfection efficiencies. T2–T5 shRNA constructs reduced
significantly the GFP level compared with control shRNA-
transfected cells (Supplementary Figure S1a online), indicat-
ing that they efficiently targeted TRIP mRNA.
NHEKs were infected with T1–T5 and control lentivirus
(LV) using a multiplicity of infection of 20–50. After 24 hours,
transduced cells were selected with puromycin (1.5 mgml–1)
for 3 days, which killed all mock-infected cells. The level of
TRIP mRNA was decreased in T2–T5-infected NHEKs by
75–90% compared with cells infected with Control A shRNA
LV (Supplementary Figure S1b online). Similar results were
obtained with Control B shRNA (data not shown). These data
confirmed the results of the TRIP-KD experiment in 293T
cells. Keratinocytes transduced with T4 and T5 shRNAs
displayed an enlarged cell size compared with controls
(Supplementary Figure S1e online), their proliferation rates
were reduced, and they were unable to attach to the culture
dish following replating.
Massive overexpression of shRNAs can lead to cell
cytotoxicity (Bridge et al., 2003; Sledz et al., 2003; Cullen,
2006; Grimm et al., 2006). The cytotoxic effect of T1–T5
shRNA expressions in NHEKs was measured by the release of
lactate dehydrogenase (LDH) into the culture medium
between 96 and 120hours postinfection. LDH release from
T4 and T5 shRNA-infected NHEKs was not significantly
different from control shRNA-infected cells (Supplementary
Figure S1c online). Moreover, cytotoxicities at 24 and
48 hours postinfection were similar in T4-, T5-, and control-
infected NHEKs (data not shown), indicating that T4 and T5
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Figure 2. TRAF-interacting protein (TRIP) expression is suppressed by
inhibition of the phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway.
(a) Quantitative reverse transcriptase PCR (RT-PCR) analysis of TRIP
expression in normal human foreskin keratinocytes (NHEKs) cultured in
low-calcium medium after treatment with different inhibitors (20 mM
PD98059, 10mM GF109203X, 5 mM SP600125, 50 mM LY294002, 10 mM
SB203580, 10mM SB202190, and 5 mM AG1478) for 24 hours. Results are
depicted as mean±SD from two (PD98059, GF109203X, SP600125) or three
(all other inhibitors) independent experiments. (b) Effect on TRIP expression in
NHEKs following rapamycin treatment for 24 hours. Results are shown as
mean±SD from three independent experiments. **Po0.01 versus control
vehicle-treated cells.
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shRNA expression was not leading to cell death during the
investigated time period. The IFN response in NHEKs infected
by T1–T5 or control shRNAs was assessed by measuring the
mRNA levels of the IFN-stimulated genes MX1 (myxovirus
resistance 1) and OAS-1 (20-50-oligoadenylate synthetase 1) at
96 hours postinfection. Both genes were significantly upre-
gulated only in T3 shRNA-infected cells (Supplementary
Figure S1d online). These data demonstrated that the effects
on cell morphology and proliferation of T4 and T5 shRNAs
were not caused by cytotoxicity. Therefore, T4 and T5
shRNAs were selected to further investigate the effect of TRIP-
KD in primary human keratinocytes.
The effect of TRIP-KD on cell proliferation was evaluated
by BrdU incorporation during the time period of 48 to
72 hours post-transduction. DNA synthesis in T4- and T5-
infected cells was significantly reduced compared with
control-infected cells (Figure 3a), indicating that the knock-
down of TRIP expression caused an arrest of keratinocyte
proliferation. To determine whether TRIP-KD induced growth
arrest in a particular phase of the cell cycle, T4- and
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Figure 3. TRAF-interacting protein (TRIP) knockdown in normal human foreskin keratinocytes (NHEKs) leads to cell growth arrest and blocks cells in G1/S
phase. (a) BrdU incorporation (mean±SEM, n¼ 3) in T4 and T5-KD cells relative to control A. (b) Cell cycle distribution in T4 (white) and T5 (grey)-KD NHEKs
compared with control A short-hairpin RNA (shRNA; black) at 96 hours postinfection (left panel) and comparison of G1/S ratios (right panel). Results
(mean±SEM) are from one experiment performed in triplicates. Similar results were obtained in three independent experiments. (c) Immunoblot analysis of
CDK4 and CDK6 (left panel) and Rb (right panel) expression in TRIP-KD NHEKs. (d) Flow cytometry analysis (mean±SEM; n¼3, 48 and 72 hours; n¼ 2,
96 hours) for viable, apoptotic, and necrotic NHEKs at 48 (black), 72 (white), and 96 hours (grey) postinfection. *Po0.05, **Po0.01, ***Po0.001 versus
control.
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T5-infected NHEKs harvested at 96 hours post-transduction
were stained with propidium iodide and analyzed by flow
cytometry. Analysis of cell cycle distribution showed a
significantly higher proportion of cells in the G1 phase,
concomitant with a decrease of cells in S phase in T4- or T5-
infected cells (Figure 3b, left panel). No significant changes
between the experimental groups were detected in the
number of cells in the G2/M phase. The G1/S ratio in T4-
and T5-infected cells was B1.5- to 2-fold higher than in
control cells, suggesting that TRIP may be required for
progression through the G1 phase or the G1/S transition in
the cell cycle (Figure 3b, right panel). Analysis of proteins
regulating the progression through the G1 and S phases of
the cell cycle showed a strong decrease in the levels of the
cyclin-dependent kinases CDK4 and CDK6 and of the
phosphorylated forms of the retinoblastoma protein Rb
(Figure 3c). Next, we asked whether T4- and T5-mediated
TRIP-KD leads to apoptosis and/or necrosis using flow
cytometry analysis of YO-PRO-1 and propidium iodide-
stained cells. There was no significant difference in
the numbers of viable, apoptotic, and necrotic cells between
T4- and T5-infected NHEKs compared with control cells at 48
and 72 hours (Figure 3d). Only a slight increase in necrotic
cells was observed in TRIP-KD keratinocytes at 96 hours post-
transduction. These results illustrated that knockdown of TRIP
in NHEKs leads to decreased cell proliferation and a higher
G1/S ratio but no significant changes in the proportion of
apoptotic or necrotic cells, suggesting that TRIP is involved in
the control of the cell cycle at the G1 and/or S stage.
Knockdown of TRIP in NHEKs promotes expression of
differentiation markers but not higher NF-jB activity
The reported experiments clearly demonstrated that inhibi-
tion of TRIP expression in NHEKs leads to cell cycle exit and
proliferation arrest. We therefore investigated whether the
cell cycle arrest in TRIP-KD NHEKs would cause increased
differentiation. NHEKs cultured in low-calcium medium
were infected with T4, T5, and control LV and selected for
3 days in puromycin. Differentiation marker expression
was assessed by qRT-PCR at 4 days post-transduction. The
results showed that the mRNA expression of keratin 1 and
profilaggrin was strongly induced in TRIP-KD cells compared
with control cells, whereas expression of keratin 5 was not
altered (Figure 4a).
As NF-kB signaling has an important role in epidermal
differentiation, we examined whether TRIP-KD increases
NF-kB activity. An LV-based reporter plasmid expressing
luciferase under the control of NF-kB-responsive elements
was used to measure NF-kB activation. NHEKs were co-
infected with the reporter and either with T4, T5, or control
LV. To assess whether NF-kB activity was increased with
time, we calculated the ratio of the luciferase activities
measured at 72 and 24 hours post-transduction (ratio 41
means an increase of NF-kB activity). Cell confluency never
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reached 100% in these experiments. The results showed that
TRIP-KD did not augment the NF-kB activity in NHEKs during
the investigated time period (Figure 4b, left panel). Baseline
luciferase activity was decreased B100-fold when the
reporter with a minimal cytomegalovirus promoter (negative
control) was used (data not shown). TNF-a treatment
increased luciferase activities in a dose-dependent manner
with the NF-kB promoter (Figure 4b, middle panel), whereas
no increase was observed with the minimal promoter (Figure
4b, right panel), demonstrating that NF-kB activation is
reliably detected. In summary, TRIP-KD decreases cell
proliferation and induces differentiation marker expression
but does not affect NF-kB signaling.
Expression of TRIP is increased in BCCs
The observed requirement of TRIP expression for keratinocyte
proliferation prompted us to evaluate TRIP expression in
BCCs. Total mRNA was extracted from five sporadic BCCs
and five normal skin biopsies, and expression levels of Gli1, a
known marker of BCCs (Dahmane et al., 1997), and TRIP
were measured by qRT-PCR. Gli1 expression was elevated by
B3-fold in BCCs compared with normal skin (Figure 5a),
indicating that the tumor biopsies contained a high propor-
tion of tumor tissue. Interestingly, TRIP expression in BCCs
was increased by B2-fold (Figure 5b), suggesting that
elevated TRIP expression may be linked directly or indirectly
to BCC formation.
DISCUSSION
The epidermal keratinocyte program of self-renewal, prolif-
eration, and differentiation requires complex regulation of
different signaling pathways to guarantee epidermal home-
ostasis and to ensure that proliferating keratinocytes are only
found in the basal layer of the epidermis. Aberrant suprabasal
proliferation is associated with a number of disease states
such as cancer, indicating that faulty regulation of keratino-
cyte commitment to exit the cell cycle and to differentiate is
one of the causes for neoplastic growth. Keratinocyte
differentiation is induced by high calcium (Hennings et al.,
1980; Yuspa et al., 1989), high cell density (Lee et al., 1998),
or growth in suspension (Tibudan et al., 2002), and is
preceded by a mandatory irreversible cell cycle arrest before
expression of differentiation markers begins. The irreversible
cell growth arrest in keratinocytes induced by TPA depends
on PKC activation (Tibudan et al., 2002; Sur et al., 2009).
PKC inhibitors partially block keratinocyte differentiation,
suggesting that activation of PKC is required for this process
(Dlugosz and Yuspa, 1993, 1994). Here, we show that
induction of keratinocyte differentiation by high calcium and
cell density decreased TRIP mRNA levels (Figure 1). Further-
more, short-term TPA exposure of keratinocytes cultured in
low-calcium medium repressed TRIP expression within
24 hours in a PKC-dependent manner (Figure 1). These
results demonstrate that TRIP mRNA expression in keratino-
cytes is strongly repressed by cell cycle withdrawal and
differentiation, indicating that TRIP expression is restricted to
proliferative cells.
Interestingly, TRIP mRNA expression in proliferating
keratinocytes was strongly decreased upon treatment with
LY294002 and rapamycin, whereas inhibitors targeting
MEK1, c-Jun N-terminal kinase, p38, and EGF signaling had
no effect (Figure 2). These data identified TRIP as specific
target of PI3K–Akt-mTOR signaling. Suppression of TRIP
mRNA by rapamycin (Javier et al., 1997), calcium, and TPA,
which block keratinocyte cell cycle progression in the G1
phase or lead to cell cycle exit, suggest that keratinocyte cell
cycle arrest negatively regulates TRIP expression. What is the
common point where these three pathways converge to
regulate TRIP? The PI3K–Akt-mTOR pathway influences
many downstream targets controlling cell proliferation, cell
growth, and apoptosis (Manning and Cantley, 2007; Hirsch
et al., 2008). Among its targets are the members of the E2F
family of transcription factors that are crucial positive
(E2F1–E2F3) and negative (E2F4–E2F6) regulators of the
G1/S transition during cell cycle progression (Chen et al.,
2009). E2F transcriptional activities are tightly regulated by
the phosphorylation-dependent association with Rb and Rb-
related pocket proteins (Chen et al., 2009). Reports that
rapamycin and LY294002 diminished the expression of
several E2F target genes established a link between the
PI3K–Akt-mTOR pathway and E2F (Brennan et al., 1999;
Bruemmer et al., 2003; Gao et al., 2003; Zohlnhofer et al.,
2004). In cell growth-arrested cells, the TRIP promoter is
bound by the E2F4-p130 complex (Cam et al., 2004) that
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Figure 5. TRAF-interacting protein (TRIP) expression is increased in basal cell carcinoma (BCC). Relative mRNA expression levels of (a) Gli1 and (b) TRIP
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downregulates gene expression in most cells (Takahashi
et al., 2000; Rayman et al., 2002). During the switch from
proliferating to differentiating keratinocytes, E2F1-pRb is
replaced by E2F4-p130 (Paramio et al., 1998, 2000; Ruiz
et al., 2004), which would be consistent with suppressed
TRIP expression. Furthermore, in mouse keratinocytes,
activation of PKC inhibits Akt activity, providing evidence
for crosstalk between PKC and Akt signaling (Li et al., 2006).
In conclusion, E2F may be the common point where the three
pathways converge; suggesting TRIP might be an E2F target
gene. Indeed, comparative sequence analysis combined with
prediction of transcription factor binding sites of the human
and mouse TRIP gene promoters detected one E2F transcrip-
tion factor binding site very close to the transcription start site
(data not shown). Interestingly, we found that TRIP is
overexpressed in BCCs. Formation of these tumors is linked
to genetic alterations in crucial components of the hedgehog-
patched signaling pathway (Gailani et al., 1996) that lead
ultimately to the activation of the zinc-finger proteins Gli1
and Gli2 (Dahmane et al., 1997). E2Fs are transcriptional
targets of Gli1 and Gli2 (Regl et al., 2004), which might
explain the increased TRIP expression in these tumors.
To define further the biological functions of TRIP, we
blocked the expression of TRIP in primary keratinocytes using
lentivirally introduced shRNAs. Knockdown of TRIP expres-
sion by 80–90% enlarged the cell size, decreased prolifera-
tion, and altered the fraction of cells in the G1 and S phases
of the cell cycle. The observed phenotype is most likely not
caused by cytotoxic effects or increased apoptosis or necrosis
(Supplementary Figures S1c and S1d online, Figure 3d). These
results correlate very well with the reduced number of BrdU-
positive cells in TRIP-KO mouse embryos and their embryo-
nic lethality around day E7 (Park et al., 2007). The increased
G1/S ratio in TRIP-KD cells suggests a role of TRIP in cell
cycle progression from the G1 to S phase. The alterations in
the quantity and degree of phosphorylation of proteins having
a crucial role in the progression from G1 to S are compatible
with a cell cycle arrest in TRIP-KD cells. As cell cycle arrest is
a prerequisite for keratinocyte differentiation, we investigated
whether decreased TRIP expression pushes cells toward
epidermal differentiation. The expression of both early
(keratin 1) and late (filaggrin) markers for epidermal
differentiation was upregulated in TRIP-KD cells (Figure 4a),
showing that this indeed was the case. This correlates with
the inability of TRIP-KD keratinocytes to reattach and grow
after passage. As overexpression of TRIP in 293T has been
reported to inhibit TNF-a-mediated NF-kB activation (Lee
and Choi, 1997; Regamey et al., 2003), growth inhibition by
TRIP shRNA could be because of NF-kB activation triggering
cell cycle arrest in epithelial cells (Kaufman and Fuchs, 2000;
Seitz et al., 2000; Dajee et al., 2003). To investigate this
issue, we measured NF-kB activity in TRIP-KD keratinocytes
using a NF-kB-dependent luciferase reporter assay. The
results demonstrated that suppression of TRIP expression
does not elevate NF-kB activity (Figure 4b). This surprising
finding indicates that TRIP is not involved in the control of
NF-kB activity during human keratinocyte differentiation.
This may be because of cell type-specific differences (primary
cells vs. cell lines) or that inhibition of NF-kB by TRIP occurs
only under nonphysiological overexpressing condition.
The results clearly underline that TRIP is implicated in the
control of cell proliferation and survival but not of NF-kB
signaling in keratinocytes. Although we have no proof that
the E3 ubiquitin ligase activity of TRIP is required for this
control function, we postulate that TRIP negatively regulates
the level of proteins, which suppress cell cycle progression
through the G1 and/or early S phase, by polyubiquitination-
mediated proteasomal degradation. Elucidation of the precise
molecular mechanism awaits the identification of TRIP
substrate protein(s). In summary, to our knowledge, TRIP is
a previously unreported regulator of keratinocyte prolifera-
tion that might also be important for proliferation control in
other cell types.
MATERIALS AND METHODS
Cell culture
HeLa, 293T, and 293FT (Invitrogen, Basel, Switzerland) cells were
cultured in DMEM containing 10% fetal bovine serum. NHEKs from
foreskin were cultured until passage 5 in low-calcium EpiLife
Medium (Cascade Biologics) containing growth supplements (ELS).
Biopsies
Biopsies from normal skin and BCCs, trimmed of adjacent normal
tissue, were snap-frozen in liquid nitrogen and stored at 80 1C. The
study, approved by the Medical Ethical Committee of the Faculty of
Biology and Medicine at the University of Lausanne, was conducted
according to the Declaration of Helsinki Principles. Informed
consent was obtained in writing from each participant.
Plasmid constructions
Five (T1 to T5) lentiviral pLKO.1-puro plasmids (MISSION; Sigma,
Buchs, Switzerland) expressing different shRNAs targeting human
TRIP mRNA (NM_005879.2) were used to repress TRIP. Lentiviral
vectors expressing a GFP-specific shRNA from the H1 promoter
(Control A) in the pRDI292 plasmid (by Professor GP Dotto) or the
non-target shRNA control vector (Control B; MISSION, Sigma) were
used as negative controls. All LV vectors carried a puromycin
selection marker. The plasmid pEKTRIP containing a GFP-STOP-
TRIP cDNA construct was obtained by cloning the TRIP cDNA into
the plasmid pEGFP-EK (by Professor D Trono).
Lentiviral production, titration, and infection
LVs were produced by co-transfecting 293FT cells with psPAX2
(Addgene, Cambridge, MA; no. 12260), pMD2.G (Addgene; no.
12259), and lentiviral vectors. The medium was changed 24 hours
post-transfection to DK-SFM (Invitrogen) supplemented with 2%
dialyzed fetal bovine serum. LV was harvested 24 hours later and the
titer was determined in HeLa cells. NHEKs were infected with
lentiviral supernatant in culture medium containing 8mgml–1
polybrene at a multiplicity of infection of 20–50. Twenty-four hours
later, cells were selected for 2 to 3 days with 1.5 mgml–1 puromycin
until mock-transduced cells were dead.
Treatment with TPA and inhibitors
NHEKs were seeded at 20,000 cells per well in a 12-well plate in
ELS. They were treated 24hours later with 100 nM TPA for 2 hours or
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with GF109203X, PD98059, SP600125, LY294002, SB203580,
SB202190, AG1478, or rapamycin at the indicated concentrations
for 24 h at 37 1C.
RNA isolation, synthesis of cDNA, and qRT-PCR
RNA was extracted from cultured cells using the RNeasy Mini Kit
(Qiagen, Hombrechtikon, Switzerland), or from biopsies using the
RNeasy Fibrous Tissue Mini Kit (Qiagen) with the TissueRuptor
(Qiagen) and treated with DNase I (Sigma). cDNA was produced
using the GeneAmp RNA PCR kit (Applied Biosystems, Rotkreuz,
Switzerland). Quantitative PCR analysis was performed with Power
SYBRGreen PCR Mastermix (Applied Biosystems) using commer-
cially available primers (QuantiTect Primer, Qiagen) using RPL13A
as endogenous control (Livak and Schmittgen, 2001).
LDH assay
LDH activity in medium and cell extracts was measured over
24 hours with the CytoTox-96 Non-Radioactive Cytotoxicity kit
(Promega, Du¨bendorf, Switzerland). Cytotoxicity was expressed as
percentage of LDH released into the culture medium relative to total
cellular LDH content.
Measuring cell proliferation using BrdU incorporation
A total of 14,000 cells per well of NHEKs were seeded into 96-well
plates 24 hours before infection with LV. Cells were selected with
puromycin (1.5mgml–1) for 48 hours and BrdU was added to the cells
during the last 24 hours of puromycin selection. Incorporated BrdU
was measured with the ELISA BrdU Chemiluminescence kit (Roche,
Rotkreuz, Switzerland).
Flow cytometry analyses
Cells were trypsinized, washed in PBS and approximately
50,000–100,000 cells were used for analysis. For apoptosis assay,
cells were stained with 20 nM YO-PRO-1 and 200 ngml–1 propidium
iodide and quantified using the LSR flow cytometer (Becton
Dickinson, Allschwil, Switzerland) and FACSDIVA 6.1.1 software
(Becton Dickinson). For cell cycle analysis, cells were fixed
overnight in ice-cold 70% ethanol, stained with 1mgml–1 of
propidium iodide (Fluka, Buchs, Switzerland), and treated with
20 mgml–1 of RNase A (Roche) for 30minutes at 37 1C. Cell cycle
distribution was analyzed using FACS Calibur and CellQuest
software with discrimination of doublets. In all, 10,000 to 20,000
events were counted during data collection.
Assay of NF-jB activity
To measure NF-kB activity, NHEKs were co-transduced with TRIP-
KD LV and reporter vectors expressing luciferase either from NF-kB
response elements or a minimal cytomegalovirus promoter (pGreen-
Fire, System Biosciences, BioCat, Heidelberg, Germany). Luciferase
activities and protein concentrations were measured with the
Luciferase Assay System (Promega) and the BCA Protein Assay Kit
(Thermo Scientific, Lausanne, Switzerland), respectively. Luciferase
activity was calculated as light units per mg protein.
TRIP knockdown assay in 293T cells
Lentiviral plasmids were co-transfected with pEKTRIP and pCruzHA-
LacZ (Santa Cruz Biotechnology, Nunningen, Switzerland) into 293T
cells. Cells extractions and b-galactosidase assays were performed as
described (Lu, 1992). For western blot analysis, rabbit anti-GFP
(Clontech, Saint-Germain-en-Laye, France) and rabbit anti-HA
(Santa Cruz) antibodies were used.
Statistical analysis
Statistical significance was calculated using Student’s t-test.
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